SequelSEC

VOLITIONRX LTD VNRX

In Vitro & In Vivo Diagnostic Substances · CIK 0000093314 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.46M
Fiscal year ended 2026-06-30
Operating income
-$19.42M
Fiscal year ended 2026-06-30
Free cash flow
-$19.58M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$72.91MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$9.01Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue42.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.17x0th
Revenue YoY growth40.0%86th
Net margin-1352.2%23th
R&D / revenue583.6%77th
Operating margin-1258.5%31th
SBC / revenue100.7%69th
FCF margin-1144.7%33th
CapEx / revenue5.2%56th

VOLITIONRX LTD (VNRX) reported revenue of $2.46M and net income of -$25.64M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VOLITIONRX LTD’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

VOLITIONRX LTD income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.46M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$19.42M
Net income-$25.64M
Research & development$9.41M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$12.48M
General & administrative$9.11M
Selling & marketing$3.36M

Balance

VOLITIONRX LTD balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.80M
Total assets$8.30M
Current assets$4.09M
Total liabilities$41.84M
Current liabilities$13.49M
Total equity incl. NCI-$33.54M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$277.36K
GoodwillUnavailable
Long-term debt$5.98M
Accounts payable$3.56M

Cash flow

VOLITIONRX LTD cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$19.56M
Capital expenditures$21.97K
Investing cash flow-$21.97K
Financing cash flow$20.35M
Net change in cash$535.00K
Stock-based compensation$939.28K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$874.46K

Derived

VOLITIONRX LTD derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$19.58M
Gross marginUnavailable
Operating margin-790.2%
FCF margin-796.7%
SBC / revenue38.2%
Current ratio0.30x
Revenue YoY growth86.3%
Net margin-1043.1%
R&D / revenue382.7%
CapEx / revenue0.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VNRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ACHV AWHL BMRA BZYR CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.